Key terms
About AEZS
Æterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AEZS news
Mar 28
11:59am ET
Aeterna Zentaris Announces Merger Approval
Mar 28
8:39am ET
Aeterna Zentaris Announces Merger with Ceapro Inc.
Mar 28
7:58am ET
Ceapro receives final court approval for merger with Aeterna Zentaris
Mar 27
8:08am ET
Aeterna Zentaris expects cash to fund operations into 2025
Mar 27
8:07am ET
Aeterna Zentaris reports Q4 EPS ($1.16) vs. ($2.56) last year
Mar 27
8:06am ET
Aeterna Zentaris completes enrollment in DETECT Phase 3 trial
Mar 12
2:37pm ET
Aeterna Zentaris, Ceapro Merger Wins Approval
Mar 12
2:11pm ET
Aeterna Zentaris, Ceapro merger approved by securityholders at special meetings
Feb 26
7:38pm ET
ISS Endorses Aeterna Zentaris-Ceapro Merger
Feb 26
7:49am ET
ISS recommends Aeterna Zentaris, Ceapro securityholders vote for merger
Feb 15
4:58pm ET
Aeterna Zentaris files to sell 2.53M warrants
No recent news articles are available for AEZS
No recent press releases are available for AEZS
AEZS Financials
Key terms
Ad Feedback
AEZS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AEZS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
